Osteoporosis International

, Volume 21, Issue 3, pp 425–431

The relationship between low bone mass and metabolic syndrome in Korean women

Original Article



We examined the relationship between low bond mass and metabolic syndrome in 2,475 Korean women. After adjustment for all covariates, mean vertebral BMD was significantly lower in women with metabolic syndrome. Moreover, age and weight adjusted vertebral BMD was significantly decreased with additional components of the metabolic syndrome.


Obesity-induced chronic inflammation is a key component in the pathogenesis of insulin resistance and metabolic syndrome. It has been suggested that proinflammatory cytokines and low-grade systemic inflammation activate bone resorption and may lead to reduced bone mineral density (BMD). The objective of this study was to determine the relationship between low bone mass and metabolic syndrome in Korean women.


This is a cross-sectional study of 2,548 women aged 18 years and over who had visited the Health Promotion Center. Physical examination and laboratory tests were performed. Vertebral BMD was measured using dual-energy X-ray absorptiometry. Metabolic syndrome was defined by National Cholesterol Education Program—Adult Treatment Panel III criteria.


Among 2,475 women, 511 (21.0%) women had metabolic syndrome. Women with abdominal obesity or hypertriglyceridemia had significantly lower vertebral BMD than women without respective components after adjustment for age, weight, and height. After adjustment for all covariates, mean vertebral BMD was significantly lower in women with metabolic syndrome (p = 0.031). Moreover, age- and weight-adjusted vertebral BMD were significantly decreased with additional components of the metabolic syndrome (p = 0.004).


These findings suggest that metabolic syndrome might be another risk factor for osteoporosis and related fractures.


Body mass index (BMI) Bone mineral density (BMD) Metabolic syndrome Obesity Osteoporosis Women 


  1. 1.
    Anonymous (1993) Consensus development conference: diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 941:646–650Google Scholar
  2. 2.
    Cooper C, Atkinson EJ, Jacobsen SJ, O'Fallon WM, Melton LJ 3rd (1993) Population-based study of survival after osteoporotic fractures. Am J Epidemiol 137(9):1001–1005PubMedGoogle Scholar
  3. 3.
    Chrischilles EA, Butler CD, Davis CS, Wallace RB (1991) A model of lifetime osteoporosis impact. Arch Intern Med 151(10):2026–2032CrossRefPubMedGoogle Scholar
  4. 4.
    Deen D (2004) Metabolic syndrome: time for action. Am Fam Physician 69(12):2875–2882PubMedGoogle Scholar
  5. 5.
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285(19):2486–2497CrossRefGoogle Scholar
  6. 6.
    Ford ES, Giles WH, Dietz WH (2002) Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutritional Examination Survey. JAMA 287:356–359CrossRefPubMedGoogle Scholar
  7. 7.
    Kim MH, Kim MK, Choi BY, Shin YJ (2004) Prevalence of the metabolic syndrome and its association with cardiovascular diseases in Korea. J Korean Med Sci 19:195–201PubMedGoogle Scholar
  8. 8.
    Kinjo M, Setoguchi S, Solomon DH (2007) Bone mineral density in adults with the metabolic syndrome: analysis in a population-based U.S. sample. J Clin Endocrinol Metab 92:4161–4164CrossRefPubMedGoogle Scholar
  9. 9.
    Ahmed LA, Schirmer H, Berntsen GK, Fonnebo V, Joakimsen RM (2006) Features of the metabolic syndrome and the risk of non-vertebral fractures: the Tromso study. Osteoporos Int 16:1899–1906Google Scholar
  10. 10.
    Ganesan K, Teklehaimanot S, Tran TH, Asuncion M, Norris K (2005) Relationship of C-reactive protein and bone mineral density in community-dwelling elderly females. J Natl Med Assoc 97:329–333PubMedGoogle Scholar
  11. 11.
    Schett G, Kiechl S, Weger S, Pederiva A, Mayr A, Petangeli M, Oberhollenzer F, Lorenzini R, Redlich K, Axmann R, Zwerina J, Willeit J (2006) High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck Study. Arch Intern Med 166:2495–2501CrossRefPubMedGoogle Scholar
  12. 12.
    Zhao L-J, Liu Y-J, Liu P-Y, Hamilton J, Recker RR, Deng H-W (2007) Relationship of obesity and osteoporosis. J Clin Endocrinol Metab 92:1640–1646CrossRefPubMedGoogle Scholar
  13. 13.
    World Health Organization (1995) Physicial status; the use and interpretation of anthropometry. Technical report series 854. WHO, GenevaGoogle Scholar
  14. 14.
    WHO Western Pacific Region, IASO and IOTF (2000) The Asia-pacific perspective: redefining obestity and its treatment, Sydney, Australia, Health Communications Australia Pty LimitGoogle Scholar
  15. 15.
    The expert committee on the diagnosis and classification of diabetes mellitus (2003) Follow-up on the diagnosis of diabetes mellitus. Diabetes Care 26(11):3160–3167CrossRefGoogle Scholar
  16. 16.
    Lee WY, Park JS, Noh SY, Rhee EJ, Sung KC, Kim BS, Kang JH, Kim SW, Lee MH, Park JR (2004) C-reactive protein concentrations are related to insulin resistance and metabolic syndrome as defined by the ATP III report. Int J Cardiol 97(1):101–106CrossRefPubMedGoogle Scholar
  17. 17.
    Diamant M, Lamb HJ, van de Ree MA, Endert EL, Groeneveld Y, Bots ML, Kostense PJ, Radder JK (2005) The association between abdominal visceral fat and carotid stiffness is mediated by circulating inflammatory markers in uncomplicated type 2 diabetes. J Clin Endocrinol Metab 90(3):1495–1501CrossRefPubMedGoogle Scholar
  18. 18.
    Cleland SJ, Petrie JR, Small M, Elliott HL, Connell JM (2000) Insulin action is associated with endothelial function in hypertension and type2 diabetes. Hypertension 35:507–511PubMedGoogle Scholar
  19. 19.
    Pepys MB, Baltz ML (1983) Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol 34:141–212CrossRefPubMedGoogle Scholar
  20. 20.
    Fröhlich M, Imhof A, Berg G, Hutchinson WL, Pepys MB, Boeing H, Muche R, Brenner H, Koenig W (2000) Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 23:1835–1839CrossRefPubMedGoogle Scholar
  21. 21.
    Chambers JC, Eda S, Bassett P, Karim Y, Thompson SG, Gallimore JR, Pepys MB, Kooner JS (2001) C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. Circulation 104:145–150PubMedGoogle Scholar
  22. 22.
    Ford ES (1999) Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care 22:1971–1977CrossRefPubMedGoogle Scholar
  23. 23.
    Yudkin JS, Stehouwer CDA, Emeis JJ, Coppack SW (1999) C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction. A potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19:972–978PubMedGoogle Scholar
  24. 24.
    von Muhlen D, Safii S, Kassal SK, Svartberg J, Barrett-Conner E (2007) Associations between the metabolic syndrome and bone health in older men and women: the Rancho Bernardo Study. Osteoporos Int 18:1337–1344CrossRefGoogle Scholar
  25. 25.
    Zhao LJ, Liu YJ, Liu PY, Hamilton LJ, Recker RR, Deng HW (2007) Relationship of obesity with osteoporosis. J Clin Endocrinol Metab 92:1640–1646CrossRefPubMedGoogle Scholar
  26. 26.
    Felson DT, Zhang Y, Hannan MT, Anderson JJ (1993) Effects of weight and body mass index on bone mineral density in men and women: the Framingham study. J Bone Miner Res 8(5):567–573CrossRefPubMedGoogle Scholar
  27. 27.
    Marcus R, Greendale G, Blunt BA, Bush TL, Sherman S, Sherwin R, Wahner H, Wells B (1994) Correlates of bone mineral density in the postmenopausal estrogen/progestin interventions trial. J Bone Miner Res 9(9):1467–1476CrossRefPubMedGoogle Scholar
  28. 28.
    Ravn P, Cizza G, Bjarnason NH, Thompson D, Daley M, Wasnich RD, McClung M, Hosking D, Yates AJ, Christiansen C (1999) Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. J Bone Miner Res 14(9):1622–1627CrossRefPubMedGoogle Scholar
  29. 29.
    De Laet C, Kanis JA, Odén A, Johanson H, Johnell O, Delmas P, Eisman JA, Kroger H, Fujiwara S, Garnero P, McCloskey EV, Mellstrom D, Melton LJ 3rd, Meunier PJ, Pols HA, Reeve J, Silman A, Tenenhouse A (2005) Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 16(11):1330–1338CrossRefPubMedGoogle Scholar
  30. 30.
    Barrett-Connor E, Kritz-Silverstein D (1996) Dose hyperinsulinemia preserve bone? Diabetes Care 19(12):1388–1392CrossRefPubMedGoogle Scholar
  31. 31.
    McLaughlin T, Abbasi F, Lamendola C, Liang L, Reaven G, Schaaf P, Reaven P (2002) Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation 106:2908–2912CrossRefPubMedGoogle Scholar
  32. 32.
    Rhee EJ, Kim YC, Lee WY, Jung CH, Sung KC, Ryu SH, Oh KW, Kim SW (2006) Comparison of insulin resistance and serum high-sensitivity C-reactive protein levels according to the fasting blood glucose subgroups divided by the newly recommended criteria for fasting hyperglycemia in 10059 healthy Koreans. Metabolism 55:183–187CrossRefPubMedGoogle Scholar
  33. 33.
    Koh JM, Khang YH, Jung CH, Bae S, Kim DJ, Chung YE, Kim GS (2005) Higher circulating hsCRP levels are associated with lower bone mineral density in healthy pre- and postmenopausal women: evidence for a link between systemic inflammation and osteoporosis. Osteoporos Int 16:1263–1271CrossRefPubMedGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2009

Authors and Affiliations

  1. 1.Family MedicineEulji University HospitalDaejeonSouth Korea
  2. 2.Family MedicineEulji University School of MedicineDaejeonSouth Korea

Personalised recommendations